Header Logo

Connection

JOHN KIRKWOOD to Proto-Oncogene Proteins B-raf

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Proto-Oncogene Proteins B-raf.
JOHN KIRKWOOD
Connection Strength
5.141
Proto-Oncogene Proteins B-raf
  1. Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends Cancer. 2020 09; 6(9):797-810.
    View in: PubMed
    Score: 0.627
  2. Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys. 2016 06 01; 95(2):632-46.
    View in: PubMed
    Score: 0.474
  3. BRAF Inhibitors and IFNa: Plus, Minus, or Indeterminate? J Natl Cancer Inst. 2016 Jul; 108(7).
    View in: PubMed
    Score: 0.463
  4. Unfolding the mutational landscape of human melanoma. J Invest Dermatol. 2015 Mar; 135(3):659-662.
    View in: PubMed
    Score: 0.434
  5. Targeted therapies: BREAKing a path for progress--dabrafenib confirms class effect. Nat Rev Clin Oncol. 2012 Sep; 9(9):496-7.
    View in: PubMed
    Score: 0.364
  6. Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma. J Immunother Cancer. 2025 Feb 12; 13(2).
    View in: PubMed
    Score: 0.216
  7. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2024 Nov 07; 391(18):1709-1720.
    View in: PubMed
    Score: 0.207
  8. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023 01 10; 41(2):186-197.
    View in: PubMed
    Score: 0.184
  9. Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling. Pigment Cell Melanoma Res. 2022 01; 35(1):66-77.
    View in: PubMed
    Score: 0.171
  10. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020 09 17; 383(12):1139-1148.
    View in: PubMed
    Score: 0.159
  11. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020 03; 21(3):358-372.
    View in: PubMed
    Score: 0.153
  12. Reply to E. Hindi? and K.R. Hess. J Clin Oncol. 2019 05 20; 37(15):1356-1358.
    View in: PubMed
    Score: 0.144
  13. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 05; 20(5):701-710.
    View in: PubMed
    Score: 0.144
  14. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol. 2018 12 10; 36(35):3441-3449.
    View in: PubMed
    Score: 0.140
  15. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017 11 09; 377(19):1813-1823.
    View in: PubMed
    Score: 0.129
  16. Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression. Cell Rep. 2016 Apr 05; 15(1):171-180.
    View in: PubMed
    Score: 0.117
  17. Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res. 2014 Jun; 24(3):207-18.
    View in: PubMed
    Score: 0.103
  18. PDGFRa up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget. 2014 Apr 15; 5(7):1926-41.
    View in: PubMed
    Score: 0.102
  19. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res. 2014 Jun 15; 20(12):3328-37.
    View in: PubMed
    Score: 0.102
  20. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014 Mar; 15(3):323-32.
    View in: PubMed
    Score: 0.101
  21. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov; 13(11):1087-95.
    View in: PubMed
    Score: 0.092
  22. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012 Jul 09; 10:85.
    View in: PubMed
    Score: 0.090
  23. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012 Jan 15; 18(2):555-67.
    View in: PubMed
    Score: 0.086
  24. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30; 364(26):2507-16.
    View in: PubMed
    Score: 0.084
  25. Systemic Therapy for Melanoma: ASCO Guideline Update. J Clin Oncol. 2023 10 20; 41(30):4794-4820.
    View in: PubMed
    Score: 0.049
  26. Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. Clin Cancer Res. 2023 02 01; 29(3):521-531.
    View in: PubMed
    Score: 0.047
  27. Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors. J Transl Med. 2022 07 25; 20(1):331.
    View in: PubMed
    Score: 0.045
  28. Prognosis and Management of BRAF V600E-Mutated Pregnancy-Associated Melanoma. Oncologist. 2020 08; 25(8):e1209-e1220.
    View in: PubMed
    Score: 0.039
  29. Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res. 2016 Jan 15; 22(2):374-82.
    View in: PubMed
    Score: 0.028
  30. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 2015 Mar; 5(3):264-73.
    View in: PubMed
    Score: 0.027
  31. Meeting report from the Third Global Workshop on Melanoma. Pigment Cell Melanoma Res. 2010 Oct; 23(5):e1-7.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.